Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Gene therapy stories

Nov 10, 2026

Beam Therapeutics base-editing sickle cell therapy succeeds in pivotal trial

Beam Therapeutics announced its base-edited sickle cell therapy met its primary endpoint in a Phase 1/2 clinical trial, potentially positioning it as a third one-time curative therapy for the disease.

Nov 10, 2026·2 sources
00
Nov 6, 2026

Novartis links two tumor cases in children to Zolgensma gene therapy

Novartis disclosed that two of nine reported tumor cases in Zolgensma recipients showed evidence of the viral delivery vector integrating into patient DNA, raising new safety questions for the gene therapy field.

Nov 6, 2026·3 sources
00

FDA launches investigation into Novartis' Zolgensma over cancer cases

The FDA is investigating a 'serious risk' of cancer linked to Novartis' spinal muscular atrophy gene therapy Zolgensma, following reports of tumor cases in children. This follows Novartis linking two tumor cases in children to the therapy.

Nov 6, 2026·2 sources
00

Sarepta halts enrollment in confirmatory Phase 3 trial of Elevidys

Sarepta Therapeutics announced it will not enroll additional patients in the confirmatory Phase 3 trial of Elevidys, its Duchenne muscular dystrophy gene therapy, a study required to maintain the drug's accelerated approval.

Nov 6, 2026·2 sources
00
Nov 5, 2026

Novartis reports nine tumor cases possibly linked to Zolgensma gene therapy

Novartis confirmed that nine patients who received its spinal muscular atrophy gene therapy Zolgensma have developed tumors following treatment, with seven cases newly reported, raising serious safety concerns about the widely used pediatric drug.

Nov 5, 2026·3 sources
00

Amgen's Repatha linked to fewer heart attacks versus Zetia in new data

New data from Amgen showed its PCSK9 inhibitor Repatha reduced heart attack risk by approximately 20% more than Zetia (ezetimibe) in patients where statins are insufficient.

Nov 5, 2026·2 sources
00
Nov 3, 2026

Ultragenyx to cut 20% of workforce after Wilson disease gene therapy failure

Ultragenyx Therapeutics announced plans to lay off approximately 20% of its employees and discontinue development of its Wilson disease gene therapy GTX-102 following a major setback in Angelman syndrome trials.

Nov 3, 2026·2 sources
00
Nov 2, 2026

FDA sets May 2027 review date for uniQure's Huntington's gene therapy

The FDA will review uniQure's gene therapy for Huntington's disease, with a decision expected in May 2027. The agency has also scheduled an advisory committee meeting.

Nov 2, 2026·2 sources
00
Oct 28, 2026

FDA releases guidance for individualized gene editing therapies

The FDA published new guidance establishing an approval framework for personalized gene editing treatments that could benefit different patient subsets with the same disease, creating a 'plug and play' pathway to accelerate individualized therapies.

Oct 28, 2026·2 sources
00

SAR402663 gene therapy shows 97% reduction in treatment burden for wet AMD in phase 2 trial

A phase 2 study presented in Vienna showed that SAR402663, a single intravitreal gene therapy injection for wet age-related macular degeneration, achieved a 97% reduction in treatment burden with positive efficacy and safety results. More than 90% of patients responded to the medium dose treatment.

Oct 28, 2026·2 sources
00
Oct 16, 2026

Estuary Biotherapeutics emerges with $103 million for kidney disease gene therapies

Estuary Biotherapeutics, a California-based biotech developing gene therapies for kidney disease, officially launched with $103 million in funding and a management team of former Biogen leaders backed by investors including Biogen.

Oct 16, 2026·2 sources
00
Oct 5, 2026

Optogenetic therapy shows promise in restoring vision for retinitis pigmentosa patients

A clinical trial of optogenetic therapy, based on Nobel Prize-winning research, demonstrated safety and partial vision restoration in patients with advanced retinitis pigmentosa, with 7 of 10 patients showing improved light sensitivity. The treatment uses gene therapy to engineer retinal cells to respond to light.

Oct 5, 2026·8 sources
00
Sep 29, 2026

UniQure's Huntington's gene therapy shows weaker benefit after four years

UniQure reported its gene therapy for Huntington's disease showed diminished benefits at four years compared to three years in a small trial, with shares plunging 48% as the results cast doubt on the treatment's long-term efficacy.

Sep 29, 2026·3 sources
00
Sep 21, 2026

Beacon Therapeutics' gene therapy succeeds in phase 2 trial for rare inherited eye disease

Beacon Therapeutics reported its experimental gene therapy improved low-light reading ability in a late-stage trial for X-linked retinitis pigmentosa (XLRP), a rare inherited eye disease that can cause blindness. The company succeeded where larger drugmakers including Johnson & Johnson and Biogen have failed.

Sep 21, 2026·2 sources
00
Sep 17, 2026

FDA approves Ultragenyx's Fayuvi, first gene therapy for Sanfilippo syndrome type A

The FDA granted full approval to Ultragenyx's gene therapy Fayuvi for Sanfilippo syndrome type A, marking the first-ever approved treatment for the ultra-rare, fatal neurodegenerative disease. The approval comes after a previous regulatory rejection and represents a significant milestone for patients with this devastating condition.

Sep 17, 2026·4 sources
00
Sep 2, 2026

UniQure seeks FDA approval for Huntington's gene therapy after reversal

Dutch biotech UniQure submitted its Huntington's disease gene therapy to the FDA for approval after the agency reversed its earlier position on the experimental treatment, following an unusually turbulent development process.

Sep 2, 2026·3 sources
00
Aug 24, 2026

FDA places clinical hold on Regenxbio gene therapy after MRI abnormalities

The FDA halted testing of Regenxbio's gene therapy for Hunter Syndrome after spinal MRI scans detected abnormalities in five trial participants. This is the second clinical hold placed on a Regenxbio gene therapy program.

Aug 24, 2026·2 sources
00
Aug 20, 2026

Ultragenyx wins first gene therapy approval with Genglycos for glycogen storage disease

The FDA approved Ultragenyx's Genglycos gene therapy for a rare glycogen storage disease, marking the company's first gene therapy clearance and providing a priority review voucher.

Aug 20, 2026·4 sources
00
Aug 13, 2026

PTC Therapeutics acquires Sangamo's Fabry disease gene therapy for $211M in bankruptcy auction

PTC Therapeutics won the bankruptcy auction for Sangamo Therapeutics' gene therapy assets with a $211 million bid. Sangamo filed for Chapter 11 bankruptcy in June after failing to find strategic alternatives.

Aug 13, 2026·2 sources
00
Aug 11, 2026

Skylark Bio doses first patient in gene therapy trial for GJB2-related deafness

Skylark Bio has dosed the first patient in its SONIX Phase 1/2 trial of SKY-GJB2, a gene therapy targeting GJB2-related hearing loss, the most common genetic cause of pediatric deafness. The trial follows earlier breakthrough gene therapy treatments that restored hearing in children born deaf.

Aug 11, 2026·3 sources
00
Aug 6, 2026

Intellia Therapeutics Reports Positive Phase 3 Results for HAE Treatment, Plans 2027 U.S. Launch

Intellia Therapeutics announced second quarter 2026 financial results alongside positive Phase 3 clinical data for lonvo-z in hereditary angioedema (HAE), with FDA biologics license application acceptance anticipated in late 2026 and U.S. commercial launch planned for first half of 2027.

Aug 6, 2026·2 sources
00
Aug 4, 2026

Biotech Startup Abandons Plans to Scale Custom CRISPR Therapies

A startup that had promised to commercialize and scale personalized CRISPR gene-editing therapies has abruptly canceled its plans, marking a setback for the custom therapeutics sector.

Aug 4, 2026·1 source
00
Aug 2, 2026

CRISPR makes prostate cancer vulnerable to immunotherapy in mice

Scientists used CRISPR gene editing to make prostate cancer cells easier for the immune system to detect and destroy, dramatically improving immunotherapy effectiveness in mice.

Aug 2, 2026·1 source
00
Jul 24, 2026

11-Year-Old London Girl Becomes First UK Patient to Receive Gene Therapy for Rare Sight-Robbing Condition

Catherine L'Estrange from North Acton became the first patient in the UK and second in the world to receive groundbreaking gene therapy for Bardet-Biedl syndrome, a rare condition that progressively causes blindness in children. The treatment, performed at St Helier Hospital in March, involves injecting healthy copies of a gene directly into the eye.

Jul 24, 2026·5 sources
00
Jul 21, 2026

Broad Institute, Boston Children's Hospital, and Jackson Laboratory Launch $160 Million Center for Rare Disease Gene Therapies

Three major research institutions announced the creation of the Center for Therapeutic Genetics, a nonprofit collaboration aimed at developing standardized genetic medicines, including base and prime editing, for rare and ultra-rare diseases that currently lack treatments.

Jul 21, 2026·9 sources
00

Personalized Antisense Therapy Shows Promise in Treating Rare Genetic Epilepsy in Two Patients

Two patients with SCN2A-related developmental epileptic encephalopathy experienced reductions in seizure frequency after receiving individualized allele-selective antisense oligonucleotides. The treatments were well tolerated, with no ASO-related serious adverse events reported in two parallel single-patient studies published in Nature Medicine.

Jul 21, 2026·1 source
00
Jul 2, 2026

FDA Expands Casgevy Gene Therapy Approval to Children as Young as Two with Sickle Cell Disease and Beta Thalassemia

The FDA has approved Vertex Pharmaceuticals' Casgevy (exagamglogene autotemcel) for patients aged two years and older with sickle cell disease and transfusion-dependent beta thalassemia, expanding from the previous minimum age of 12 years. The approval was granted under the agency's Commissioner's National Priority Voucher program.

Jul 2, 2026·3 sources
00
Jun 22, 2026

FDA Reverses Rejection of Regenxbio's Rare Disease Gene Therapy

The FDA indicated it would reverse its earlier rejection of Regenxbio's gene therapy for a deadly childhood disease, stating that existing data would be sufficient to support an accelerated approval bid. The reversal represents a significant policy shift.

Jun 22, 2026·2 sources
00
May 14, 2026

Regenxbio's Duchenne Gene Therapy Succeeds in Clinical Trial, Paving Way for FDA Submission

Regenxbio announced its experimental gene therapy for Duchenne muscular dystrophy succeeded in a clinical trial, enabling the company to move forward with an FDA submission.

May 14, 2026·1 source
00
May 13, 2026

Scientists Link Boy's Tumor to Gene Therapy Viruses in Rare Safety Finding

Doctors have directly linked a pediatric patient's tumor to gene therapy treatment viruses, marking a rare documented case of this safety risk. The finding comes as the gene therapy field grapples with safety-efficacy tradeoffs, with separate research showing that drugs designed to improve gene therapy safety may reduce effectiveness.

May 13, 2026·2 sources
00
May 12, 2026

Astellas Returns to Gene Therapy for Rare Disease XLMTM After Previous Trial Disaster

Five years after a disastrous trial where some boys died while others had astonishing recoveries, Astellas is returning with a revised gene therapy treatment for X-linked myotubular myopathy (XLMTM), offering new hope to a devastated rare disease community.

May 12, 2026·2 sources
00
May 6, 2026

Duke University Develops Gene Therapy to Help Hearts Heal After Heart Attacks

Researchers at Duke University are developing a gene therapy treatment designed to help repair heart damage following heart attacks, potentially changing how doctors treat cardiac injury from the leading cause of death in the U.S.

May 6, 2026·1 source
00
May 4, 2026

Latus Bio Raises $42 Million to Advance Huntington's Disease Gene Therapy Trial

Latus Bio secured $42 million in funding as it prepares to seek FDA approval to begin a clinical trial for its gene therapy targeting Huntington's disease, a progressive neurodegenerative disorder.

May 4, 2026·1 source
00
Apr 27, 2026

Intellia Reports Positive Pivotal Trial Results for CRISPR-Based Treatment of Rare Swelling Disease

Intellia Therapeutics announced that its CRISPR-based gene editing treatment reduced swelling attacks in a pivotal trial for hereditary angioedema, a rare genetic disease. The results advance the CRISPR field's one-and-done treatment approach toward potential regulatory approval.

Apr 27, 2026·1 source
00
Apr 24, 2026

FDA Approves First Gene Therapy for Hereditary Hearing Loss

The FDA has greenlit a first-of-its-kind gene therapy to treat a rare form of hereditary hearing loss, marking a breakthrough that could pave the way for other hearing impairment treatments. Follow-up research confirms the therapy yields lasting hearing gains for patients with inherited deafness.

Apr 24, 2026·2 sources
00
Apr 22, 2026

Gene Therapy for Inherited Deafness Shows Lasting Hearing Restoration Years After Treatment

International clinical trial results show that gene therapy for a rare form of genetic deafness successfully restored hearing in 90% of participants, with improvements lasting years after treatment. The study was co-led by Mass General Brigham and China's Eye & ENT Hospital of Fudan University.

Apr 22, 2026·2 sources
00
Apr 21, 2026

Breakthrough Prize Awards $3 Million Each to Six Scientists for Gene Therapies and KRAS Research

The 2026 Breakthrough Prize honored six laureates with $3 million awards for discoveries including gene therapies for inherited blindness and sickle cell disease, as well as groundbreaking work on KRAS cancer targets. Boston-area researchers were among those recognized.

Apr 21, 2026·2 sources
00
Apr 17, 2026

Roche Launches New Phase 3 Trial of Elevidys for European Approval

Roche is initiating another Phase 3 clinical trial of the controversial Duchenne muscular dystrophy gene therapy Elevidys, aiming for potential approval in European markets.

Apr 17, 2026·1 source
00

Top claims

  • ▪Beam Therapeutics plans to submit an approval application for risto-cel to the U.S. Food and Drug Administration as early as the end of 2026
  • ▪Beam Therapeutics announced its base-editing treatment ristoglogene autogetemcel met its primary endpoint of freedom from severe vaso-occlusive crises
  • ▪If approved, risto-cel would enter a sickle cell treatment market that includes approved genetic therapies Casgevy and Lyfgenia, alongside hydroxyurea, l-glutamine, blood transfusions, and stem cell transplants

People involved

Catherine L'Estrange

Subtopics

Drug Policy, Pricing & Approval30Drug Approval and Clinical Trials26Clinical trials16Clinical Genomics & Genetics7Genetic diseases7Rare diseases7Drug safety6Cancer & Oncology5FDA drug approval5Pharmaceutical Industry5Neurodegenerative disease4Pharma4Biotech innovation3Clinical evaluation3Clinical Trial Design & Evaluation3CRISPR gene editing3Gene editing3Genetic disorders3Personalized medicine3Post-market surveillance3Accelerated approval pathways2Biotechnology2FDA regulation2Lyme disease treatment2

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories